📋 Tender Overview
Charles River Laboratories International Inc. announced that the Company has been selected by Alzheimers Research UK to join the Dementia Consortium. The Consortium is a global charity-industry partnership aimed at funding promising research from academia and helping progress projects with the scale and strength of industry supporters.The Consortium invests in academic led research projects typically 2-3 years in duration which aim to provide validation of targets for the treatment of dementia or explore the tractability of the target for drug discovery. Projects already funded include among others novel small molecule inhibitors of the NLRP3 inflammasome inhibitors of the interaction between key proteins involved in the proliferation of microglia and the role of immune system regulators and receptors in neurodegeneration. Applications for innovative new dementia targets are now being accepted by Alzheimers Research UK in the second phase of the Dementia Consortium and new projects are now under way.As the latest contract research organization CRO partner chosen by Alzheimers Research UK to join the Consortium Charles River scientists will collaborate with grant recipients on selected projects consulting on areas including biological assay development and screening high-throughput screening and medicinal chemistry. Grant holders will have regular project review meetings with members of the Dementia Consortium and Charles Rivers unique integrated drug discovery approach will be leveraged with academic investigators to help them navigate their projects. Successful projects that generate novel chemistry may then be considered for licensing to industry partners to facilitate the progression of novel treatments into the clinic.Approved QuotesWe see an incredible need to research innovative solutions to neurodegenerative diseases. The Dementia Consortium brings together the best minds from academia and industry to progress candidates through the drug discovery and development process. We are proud to be part of the important work theyre doing Birgit Girshick Corporate Executive Vice President Discovery Safety Assessment Biologics Testing Solutions and Avian Vaccine Services Charles River.Dementia impacts nearly 50 million people worldwide a number that is expected to triple by 2050. Treating dementia poses an enormous medical challenge and we are excited to leverage Charles Rivers early drug discovery expertise in our effort to tackle it. Carol Routledge PhD Director of Research Alzheimers Research UK.